Glucose counterregulation in type 2 diabetes mellitus

Diabetic Medicine

Volumn 18, Issue 7, 2001, Pages 519-527

  De Galan, B E ^a   Hoekstra, J B L ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

Glucose counterregulation; Hypoglycaemia; Insulin resistance; Metabolic control; Residual cell function; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT;

CONTROLLED STUDY; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW;

AWARENESS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; HYPOGLYCEMIA; INSULIN;

EID: 0034851707     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2001.00610.x     Document Type: Review

References (60)

1. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction
2. Lack of glucagon response to hypoglycemia in diabetes: Evidence for an intrinsic pancreatic alpha cell defect
3. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus
4. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion
5. Hypoglycemia unawareness in IDDM
6. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type 1 diabetes
7. Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus
8. The prevalence of impaired glucose counterregulation during an insulin-infusion test in insulin-treated diabetic patients prone to severe hypoglycaemia
9. Intermittent hypoglycemia impairs glucose counterregulation
10. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
12. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
14. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
15. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes
16. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin
17. Occurrence of low blood glucose concentrations during the afternoon in type 2 (non-insulin-dependent) diabetic patients on oral hypoglycaemic agents: Importance of blood glucose monitoring
18. Drug-induced hypoglycemic coma in 102 diabetic patients
19. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents
20. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas
21. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study
22. Drug-induced hypoglycemia. A review of 1418 cases
23. The nature of hyperglucagonemia in diabetes mellitus
24. Hormonal responses to insulin infusion in diabetes mellitus
25. Studies on plasma glucagon concentration in maturity-onset diabetics with autonomic neuropathy
26. Counterregulatory hormone release and glucose recovery after hypoglycemia in non-insulin-dependent diabetic patients
27. Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes
28. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions
29. Counterregulation in type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis
30. Effects of recombinant human insulin-like growth factor I and insulin on counterregulation during acute plasma glucose decrements in normal and type 2 (non-insulin-dependent) diabetic subjects
31. Counterregulatory hormone responses to hypoglycemia in the elderly parent with diabetes
32. Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus
33. Differential effects of human and animal insulin on the responses to hypoglycemia in elderly patients with NIDDM
34. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes
35. Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM
36. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes
37. Hypoglycaemic counterregulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes
38. Implications of the Diabetes Control and Complications Trial
39. Does the choice of treatment for type 2 diabetes affect the physiological response to hypoglycaemia?
40. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis
41. Altered responses to hypoglycemia of healthy elderly people
42. Hypoglycaemia and type 2 diabetes: Insulin therapy
43. Effect of physiological hyperinsulinemia on counterregulatory hormone responses during hypoglycemia in humans
44. Counterregulatory hormones oscillate during steady-state hypoglycemia
45. Contribution of autonomic neuropathy to reduced plasma adrenaline responses to hypoglycemia in IDDM: Evidence for a nonselective defect
46. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin
47. Glibenclamide decreases glucagon release during mild hypoglycaemia
48. Counterregulatory response to hypoglycemia differs according tothe insulin delivery route, but does not affect glucose production in normal humans
49. The use of tolbutamide-induced hypoglycemia to examine theintraislet role of insulin in mediating glucagon release in normal humans
50. Defective glucose counter-regulation in type 2 diabetes
51. Antecedent hypoglycemia does not alter the physiological response to subsequent hypoglycemia in NIDDM
52. Long-term intensive insulin therapy in IDDM: Effects onHbAlc, risk for severe and mild hypoglycaemia, status of counter-regulation and awareness of hypoglycaemia
53. Plasma glucose concentrations at the onset of hypoglycemic symptoms inpatients with poorly controlled diabetes and in nondiabetics
54. Stimulation of counter-regulatory hormonal responses in diabetic man by a fall in glucose concentration
55. Counterregulatory hormonal responses to hypoglycaemia in type 1 (insulin-dependent) diabetes: Evidence for diminished hypothalamic-pituitary hormonal secretion
56. Intensified treatment and education of type 1 diabetes as clinical routine. A nationwide quality-circle experience in Germany. ASD (the Working Group on Structured Diabetes Therapy of the German Diabetes Association)
57. The Berson memorial lecture. Insulin-glucagon relationships in the defense against hypoglycemia
58. Assessment of insulin action in NIDDM in the presence of dynamic changes in insulin and glucose concentration
59. Effect of epinephrine on pancreatic beta-cell and alpha-cell function in patients with NIDDM
60. Counterregulation in peripheral tissues: Effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue